Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
Latest Information Update: 27 Aug 2023
Price :
$35 *
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Advantagene; Candel Therapeutics
- 24 Jul 2023 Planned End Date changed from 1 May 2022 to 1 Dec 2024.
- 25 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology